Delatestryl and Breastfeeding
It is unclear if the active ingredient in Delatestryl (testosterone enanthate) passes through breast milk. However, the medication does have the potential to decrease the supply of breast milk, increase the risk of postpartum blood clots, and cause other problems. Thus, women who are breastfeeding are typically advised to avoid Delatestryl.
Delatestryl® (testosterone enanthate) is a prescription medication most often used in men, as it contains testosterone. The manufacturer warns that breastfeeding women should not use Delatestryl. The only approved use of Delatestryl in women is the treatment of certain cases of late-stage breast cancer.
It is not known if testosterone -- the active ingredient in Delatestryl -- passes through breast milk in large amounts or if it could cause problems in nursing infants. There might be particular concern for female infants.
In addition, testosterone was once used to suppress lactation in women who chose not to breastfeed. It seems that testosterone inhibits prolactin, a hormone important for breastfeeding. Because Delatestryl has the potential to decrease your breast milk supply and may increase the risks of postpartum blood clots, you should not use this medicine while breastfeeding.
You should discuss breastfeeding and Delatestryl use with your healthcare provider. Each woman's situation is different, and you and your healthcare provider understand your situation best. After considering what you want and expect, as well as your current health situation, the two of you can make a shared decision that is right for you. In almost all conceivable circumstances, it is likely not a good idea for breastfeeding women to use Delatestryl.